×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
BridgeBio Pharma Sees RS Rating Climb To 78
Investor's Business Daily
The Relative Strength (RS) Rating for BridgeBio Pharma (BBIO) headed into a higher percentile Friday, as it got a lift from 67 to 78.
15 hours ago
BridgeBio Oncology Therapeutics Completes $200 Million Private Financing | News & Events | Goodwin
Goodwin Law Firm
The Goodwin Life Sciences team advised BridgeBio Pharma on a private financing of its former subsidiary, TheRas, Inc. to accelerate the...
3 weeks ago
BridgeBio Pharma's (BBIO) “Buy” Rating Reaffirmed at HC Wainwright
Defense World
HC Wainwright reaffirmed their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research report sent to investors...
13 hours ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
2 weeks ago
BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM
BioSpace
Additional analyses from BridgeBio Pharma's late-stage study show the oral drug candidate improved clinical outcomes in transthyretin...
1 day ago
BridgeBio reports additional positive data for acoramidis in ATTR-CM (NASDAQ:BBIO)
Seeking Alpha
May 29, 2024 5:11 PM ETBridgeBio Pharma, Inc. (BBIO) StockPFEBy: Val Brickates Kennedy, SA News Editor. cardiomyopathy. GreenApple78/iStock via Getty Images.
2 days ago
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
PR Newswire
PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq:...
4 months ago
UBS lowers BridgeBio Pharma shares target, cites upcoming clinical data By Investing.com
Investing.com
On Tuesday, UBS has adjusted its price target on BridgeBio Pharma (NASDAQ:BBIO) shares, now aiming for a $47.00 target, a decrease from the...
3 days ago
Latham & Watkins Advises BridgeBio Pharma in US$1.25 Billion Cross-Border Funding
Latham & Watkins LLP
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical focused on genetic diseases and...
4 months ago
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
GlobeNewswire
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
2 weeks ago